This observational study will evaluate the safety and efficacy of MabThera/Rituxan (rituximab) plus chemotherapy as first-line treatment in patients with diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL). Data will be collected from each patient during the 6 months of induction treatment and for up to 3 years of follow-up.
Study Type
OBSERVATIONAL
Enrollment
314
The Affiliated Hospital of Military Medical Sciences(The 307th Hospital of Chinese PLA)
Beijing, China
Safety: Incidence of adverse events
Time frame: 4.5 years
Overall Response Rate (complete response + partial response)
Time frame: 4.5 years
Progression-free survival, defined as time from first treatment to lymphoma progression or death
Time frame: 4.5 years
Overall Survival, defined as time from 1st treatment to death of any cause
Time frame: 4.5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
the First Hospital of Jilin University
Changchun, China
Xiangya Hospital of Centre-South University
Changsha, China
Changzhou First People's Hospital
Changzhou, China
Daqing Oilfield General Hospital
Daqing, China
The First People's Hospital of Foshan
Foshan, China
Fuzhou General Hospital, PLA Nanjing Military Area Command
Fuzhou, China
Fujian Provincial Hospital
Fuzhou, China
Nanfang Hospital, Southern Medical University
Guangzhou, China
The affiliated Hospital of Guiyang Medical College
Guiyang, China
...and 14 more locations